XenoPort, Inc. (XNPT): Nasdaq are a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. Our most advanced product candidate is currently being evaluated in a Phase 3 clinical program for the treatment of restless legs syndrome, [...]
Penny Stock Pick Feature XNPT XenoPort, Inc.
XenoPort, Inc. (XNPT): Nasdaq are a biopharmaceutical company focused on developing a portfolio of internally… [more]
Penny Stock Pick Feature CXM Cardium Therapeutics, Inc.
We have added Cardium Therapeutics, Inc. (CXM): NYSE Amex to our featured and our watch list today. As… [more]
Penny Stock Pick Feature ALXA Alexza Pharmaceuticals, Inc.
We have added Alexza Pharmaceuticals, Inc. (ALXA): Nasdaq to our featured and our watch list today with… [more]
Featured Penny Picks
Penny Stock Pick Feature CXM Cardium Therapeutics, Inc.
We have added Cardium Therapeutics, Inc. (CXM): NYSE Amex to our featured and our watch list today. As our subscribers know we just love the pharma tech plays specially the smaller ones as they could have potential for some big moves. Cardium Therapeutics, Inc. (CXM): NYSE Amex Cardium Therapeutics is focused on the acquisition and [...]
Penny Stock Pick Feature ALXA Alexza Pharmaceuticals, Inc.
We have added Alexza Pharmaceuticals, Inc. (ALXA): Nasdaq to our featured and our watch list today with the upcoming FDA meeting in October for AZ-004 Staccato loxapine, we ask you to do some research on this company. We just love the pharma tech plays specially the smaller ones as they could have potential for big [...]
Top News
Penny Stock Pick Feature BPAX Biosante Pharmaceuticals, Inc.
We have added Biosante Pharmaceuticals, Inc. (BPAX): Nasdaq to our featured and our watch list today. As our subscribers know we just love the pharma tech plays specially the smaller ones as they could have potential for big moves. Biosante Pharmaceuticals, Inc. (BPAX): Nasdaq focuses on products for female sexual health, menopause, contraception, and male [...]
Myrexis Reports Anti-Tumor Activity in a Subset of Patients From Ongoing Phase 2 Azixa
Myrexis. (Nasdaq: MYRX) a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced a poster presentation of its lead product candidate Azixa(TM) (verubulin, MPC-6827) at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day in Montreal, Canada. Dr. Sean Grimm of the Northwestern University Brain Tumor Institute was the [...]
Alexza: FDA declines treatment for agitation
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) Alexza Pharmaceuticals Inc., the Mountain View, Calif., drug developer, said on Monday that the U.S. Food and Drug Administration declined to clear for marketing AZ-004, a potential rapid treatment for agitation in patients with schizophrenia or bipolar disorder. The drug, generically loxapine, is taken by inhalation. In a complete [...]
Press Releases
XenoPort Reports Results from a Phase 2b
XenoPort, Inc. (Nasdaq:XNPT) announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI). In this study, subjects who experienced GERD [...]
ACUROX(R) Tablets New Drug Application Accepted for Filing With a Priority Review Classification
ACUROX(R) Tablets New Drug Application Accepted for Filing With a Priority Review Classification Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) today announced that it has been informed by King Pharmaceuticals Research and Development Inc. (King) that King’s New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets was accepted for filing by the US Food and Drug Administration (FDA) [...]
FDA Accepts ANX-530 NDA for Filing
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine. The filing of the Exelbine NDA means the FDA has made a threshold determination that it is sufficiently complete to [...]
Stock Chit Chat
Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) announced today that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference. The Alexza presentation will be on Friday, August 13, 2010 at 10:40 am ET. The presentation will be webcast from the Southampton [...]
RPRX Back in Play
Penny stock picks gave the heads up on RPRX in June on Proellex lift, and now there could be a chance to make more money on this penny stock play with Androxal. And we have are adding this to our radar on FDA news for Androxal. RPRX : (Nasdaq) Are awaiting response from the FDA [...]
ARNA Arena Pharma stock offering
Arena Pharmaceuticals Inc. said Friday it expects to receive about $60 million before expenses from a direct public offering of stock to entities tied to the health investment firm Deerfield Management. Arena, which is based in San Diego, said it will sell a total of about 8.9 million shares for $6.70 per share. The offering [...]